Drug Profile
Research programme: obesity therapies: Wyeth Pharmaceuticals
Latest Information Update: 03 Oct 2011
Price :
$50
*
At a glance
- Originator Haptogen
- Class Antibodies
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 14 Dec 2005 Preclinical trials in Obesity in Scotland (unspecified route)